Skip to main content
. 2019 May 29;317(2):G127–G140. doi: 10.1152/ajpgi.00064.2019

Fig. 6.

Fig. 6.

Specificity of hepatitis B virus (HBV) core peptide18–27-human leukocyte antigen-A2 (HLA-A2) in recognizing the major histocompatibility complex I (MHC) complex of HBV-transfected HepG2.2.15 cells. A: HepG2 cells and HBV-transfected HepG2.2.15 cells were used for immunoflourescece staining of HBV core peptide (18–27)-HLA-A2 MHC complex. Green shows staining of HBV peptide-HLA-A2 Alexa fluor 488 staining. Staining was visualized using a ×63 lens in a LSM 710 confocal microscope. B: HepG2 cells unpulsed (without HBV 18–27 peptide) and HepG2 cells pulsed with 5 µM HBV 18–27 peptide for 4 h, and then HBV core peptide (18–27)-HLA-A2 MHC complex staining was measured by flow cytometry with antibody to HBV peptide-HLA-A2 followed by exposure to Alexa fluor 647 secondary antibody. Alexa fluor 647 secondary antibody was used as control. Data were collected on a BD LSR2 flow cytometer and analyzed using BD FACSDiva software v.6.0.